Natriuretic peptide

Cardiac Marker Testing Market by Product, Component, Disease, End-user and Region - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Health, Cardiology, Natriuresis, POCT, Government, Growth, Investment, Natriuretic peptide, CAGR, Component, Membrane protein, CK-MB, POC, Biomarker, Troponin I, Reagent, BNP, Myoglobin, Heart failure, USD, Lab, Myocardial infarction, Medical device, Disease

The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.

Key Points: 
  • The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.
  • Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type
    Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers.
  • The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021.
  • In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market.

Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference

Retrieved on: 
Thursday, August 13, 2020
Aphrodisiacs, Peptides, Branches of biology, Canaccord Genuity, Peptide hormones, Genuity, Bremelanotide, Organ systems, Natriuretic peptide, Melanocortin, Molecular biology

CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40th Annual Growth Conference in a Fireside Chat today at 10:30 am ET.

Key Points: 
  • CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ --Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40th Annual Growth Conference in a Fireside Chat today at 10:30 am ET.
  • Carl Spana, Ph.D., President and Chief Executive Officer and Stephen T. Wills, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, participated in the Fireside Chat hosted by John Newman of Canaccord Genuity.
  • Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
  • For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com .

Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual

Retrieved on: 
Monday, March 30, 2020
Cytokinetics, Amgen, Ejection fraction, Natriuretic peptide, Peptide, Life sciences, Companies, Industries

Patients were also required to have a left ventricular ejection fraction (LVEF) 35% and elevated natriuretic peptides.

Key Points: 
  • Patients were also required to have a left ventricular ejection fraction (LVEF) 35% and elevated natriuretic peptides.
  • Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics, with funding and strategic support from Servier.
  • Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights.
  • For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting

Retrieved on: 
Thursday, September 12, 2019
Clinical research, Design of experiments, Health, Knowledge, Research, Urinary system, Natriuretic peptide precursor C, Natriuretic peptide, Achondroplasia, CNP, Placebo-controlled study, Randomized controlled trial

We are committed to fully understanding the patient experience so as to inform our TransCon CNP program including aspects of achondroplasia beyond skeletal growth.

Key Points: 
  • We are committed to fully understanding the patient experience so as to inform our TransCon CNP program including aspects of achondroplasia beyond skeletal growth.
  • TransCon CNP has recently advanced into the global phase 2 ACcomplisH Trial, a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of TransCon CNP in approximately 60 subjects with achondroplasia.
  • TransCon CNP is a long-acting prodrug of C-type natriuretic peptide (CNP) in development as a potential therapy for children with achondroplasia.
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.